Search
Immunovant Inc
IMVTAdd to Watchlist
38.220USD
+0.600+1.59%
Close 06/24, 16:00（ET）Quotes delayed by 15 min
7.79BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated:Analyst Rating
Based on
18
analysts
Buy
Current Rating
43.267
Target Price
+22.43%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
561
Total
5
Median
6
Average
Company name
Ratings
Analysts
Immunovant Inc
IMVT
18
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
IQVIA Holdings Inc
IQV
26
CRISPR Therapeutics AG
CRSP
26
argenx SE
ARGX
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Immunovant Inc's price target?
Analysts forecast that Immunovant Inc's price target is USD 44.00, with the highest forecast at USD 57.00 and the lowest forecast at USD 16.00.
How have Immunovant IncIMVT's recent earnings per share performed?
The market expectation was USD -0.73, while Immunovant IncIMVT's earnings per share (EPS) for the previous quarter was USD -0.61. EPS for the next quarter is expected at USD -0.60.
What is the analyst rating for Immunovant Inc?
Based on the ratings of Immunovant Inc's stock from 18 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
